AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06284161 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quadriceps Combined Test
Description: The recording of the motor response on the quadriceps is done using self-adhesive surface electrodes on the motor point of the vastus medialis muscles (active electrodes) and on the patella (reference electrode), using a classic electromyography device that allows calculations and measurements of amplitude, duration and speed.
Study NCT05399797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational training
Description: Pharmacists in the intervention group will given detailed online educational training on how to recognize and manage acute uncomplicated urinary tract infections in adults.
Study NCT06206187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated detection of the intracardiac thrombus through deep learning
Description: A deep learning model will identify the intracardiac thrombus. The AI model will produce an assessment of intracardiac thrombus using video based features.
Study NCT06206187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrophysiologist judgment of the intracardiac thrombus
Description: Cardiac electrophysiologists use their own experience to determine whether there is intracardiac thrombus
Study NCT04134039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyurethane (PU) condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
Study NCT04134039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural Rubber Latex (NRL) condom
Description: A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
Study NCT06180057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid
Description: Two capsules were administered orally
Study NCT06180057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chenodeoxycholic acid leadiant
Description: Two capsules were administered orally
Study NCT06032637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pfannenstiel incision
Description: Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
Study NCT04900571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 MG
Description: Comparison of alleviating post-operative pain between nitrofurantoin and calcium hydroxide
Study NCT06032637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supra-umbilical transverse incision
Description: Patients randomized to the supra-umbilical transverse incision arm will receive a transverse skin incision 3-4cm above the umbilicus, extending laterally to the semilunar lines, without panniculus retraction. The subcutaneous tissue will be bluntly dissected until the anterior rectus sheath is exposed. The rectus sheath will be incised transversely using electrocautery for hemostasis, avoiding injury to the superior epigastric vessels. The rectus muscles will be split manually along the midline using blunt dissection. The peritoneum will be transversely incised and the hysterotomy extended laterally to deliver the fetus. The visceral peritoneum will not be closed. The rectus muscles will not be re-approximated. The subcutaneous tissue will not be irrigated but closed if over 2cm depth. The skin will be closed with non-absorbable suture subcuticularly.
Study NCT05414994 — intervention group
Intervention type: OTHER
Intervention: Eye swab
Description: This is a simple swab under the eyelids of both eyes
Study NCT06236555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 8-iso Prostaglandin F2α and Adenosine Deaminase
Description: We took gingival crevicular fluid samples from patients who applied to our clinic and evaluated the -iso Prostaglandin F2α and Adenosine Deaminase levels in the samples.
Study NCT05026762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Following the collection of the baseline data, the study participant will be assigned to a volunteer(medical student) to begin the social phone calls. The first phone call will be scheduled to occur within one week of the consent and baseline assessments. A minimum of one social phone call will occur each week for 6-weeks. Each phone call is expected to last up to 1 hour.The calls will be unstructured and designed simply to engage in conversation with the participant. The length of the phone calls, days and times will be recorded by the volunteer along with a short journal entry describing the conversation topics and any information that stood out to the volunteer.At the end of the 6-weeks phone calls, a group session will be held with the volunteers to engage in a debriefing and narrative medicine session.
Study NCT06426420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FTIR spectroscopy analysis
Description: ATR-FTIR Spectroscopy analysis combined with machine learning algorithms.
Study NCT06147271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2i
Description: A randomized clinical trial of superiority with active control (2 arms), with central randomization to evaluate the efficacy and safety of adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.
Study NCT05604898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Description: 608 will be administered subcutaneously.
Study NCT05604898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.
Study NCT05604898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
Description: 608 will be provided at pre-specified time intervals.
Study NCT05604898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Study NCT05604898 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
Study NCT04552899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRM-151 (Zinpentraxin Alfa)
Description: A 10 mg/kg IV infusion of PRM-151 based on the participants weight will be administered on Days 1, 3 and 5 followed by infusions Q4W to Week 48.
Study NCT05449665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 1 - Control
Description: Control diet (30% Fat, 15% Protein, 55% Carbohydrate, Fibre rising from 10 to 16g/d).~Fed to energy balance (1.5 x Resting Metabolic Rate, RMR).
Study NCT05449665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 2 - High Fibre
Description: High Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 30g/day Fibre). Fed ad libitum, contains 20g/day pectin (split over breakfast, lunch and dinner) in drinks/yoghurts which will be compulsory to consume and 10g/day fibre coming from the diet provided.
Study NCT05449665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase 3 - Low Fibre
Description: Low Fibre diet (30% Fat, 15% Protein, 55% Carbohydrate, 10g/day Fibre). Fed ad libitum.
Study NCT04552899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching PRM-151 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
Study NCT05303701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 Placebo
Description: 0.9% normal saline
Study NCT05303701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GV1001 Placebo
Description: 0.9% normal saline
Study NCT05303701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001 1.12mg
Description: Lyophilized peptide from hTERT
Study NCT05303701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GV1001 1.12mg
Description: Lyophilized peptide from hTERT
Study NCT04673773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Massive Open Online Course
Description: Same as intervention
Study NCT06041204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
Study NCT06041204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Participants will receive 2.5mg letrozole tablets orally daily for 5 days starting on day 3 of menstrual cycle. The 2.5mg dose will be maintained for at least the first 3 cycles. If no ovulation after 3 cycles, dose cautiously increased up to 7.5mg maximum. Once minimum ovulation dose determined, it will be continued for up to 6 cycles total or until pregnancy occurs. Compliance monitored by pill counts and diary. Ovulation assessed by follicular monitoring and progesterone levels. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Maximum treatment duration is 6 ovulatory cycles or 6 months. Tablets taken at same time each day.
Study NCT06041204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine 25 Mcg (0.025 Mg) Oral Tablet
Description: Participants will take letrozole at same doses as letrozole only group. Also receive levothyroxine starting at 25mcg orally once daily, titrated by 25mcg every 4 weeks to reach normal TSH, maximum 100mcg daily. Once appropriate dose determined to normalize TSH, it is maintained throughout treatment period. Compliance monitored by pill counts, TSH levels, and diary. Treatment continues for up to 6 ovulatory cycles or until pregnancy, whichever is first, maximum 6 months. Ovulation assessed by monitoring and progesterone. Routine antenatal care if pregnant. Adverse effects monitored and managed per guidelines. Participants followed for multiple pregnancies. Letrozole and levothyroxine taken daily at same time. All other procedures same as letrozole only group.
Study NCT06376968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioLogic Fusion
Description: Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.
Study NCT05423834 — intervention group
Intervention type: DRUG
Intervention: Tenofovir alafenamide
Description: Chronic hepatitis B patients who are receiving TAF as antiviral therapy for CHB, who were previously treatment naïve.
Study NCT05423834 — intervention group
Intervention type: DRUG
Intervention: Entecavir
Description: Chronic hepatitis B patients who are receiving ETV as antiviral therapy for CHB, who were previously treatment naïve.
Study NCT06003361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital CBT
Description: An app-based intervention based on principles from cognitive behavioral therapy for depression.
Study NCT06003361 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist
Description: Participants will wait for 5 weeks prior to receiving the intervention
Study NCT04772898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The hippotherapy involves occupational therapy while being on a horse.
Study NCT04772898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hippotherapy
Description: The hippotherapy involves occupational therapy while being on a horse.
Study NCT06277544 — intervention group
Intervention type: PROCEDURE
Intervention: lateral ankle ligament repair or reconstruction
Description: repair or reconstruction procedure for lateral ankle ligament
Study NCT04919707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Header Session
Description: Participant fit with commercially available Storelli ExoShield Head Guard that has been fit with head impact sensors; participant completes a set of basic standing header tasks which mimic the types of purposeful heading anticipated to occur in actual play in soccer practice and games.
Study NCT04919707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Session
Description: Scanning will include high resolution T1w imaging for 3-dimensional structural analyses, DTI and resting-state MRI for assessment of structural and functional brain network connectivity, as well as susceptibility-weighted imaging and multicomponent relaxometry to assess for microhemorrhages and myelin damage.
Study NCT05158569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow breathing exercise group
Description: The patient will be first asked to close one nostril with a thumb and slowly breathe in completely through the other for 6 seconds. This nostril will be then closed and the patient will exhale through the other nostril over a period of 6 seconds. These steps complete one breathing cycle. An attempt will be made to keep the breathing rate is about 5-6 breaths per minute. Such alternate nostril breathing cycles will be repeated continuously for a period of about 15 minutes (3 sets of 5 minutes) in one sitting.
Study NCT05158569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercise group
Description: Patients would be instructed to Sit or lie down in a comfortable place and put their hands on their belly.~Relax the muscles in their neck and shoulders. Breathe in slowly through the nose, keeping their mouth closed. Feel the lungs fill with air and inflate like a balloon while their belly moves outward. Such breathing cycles will be repeated continuously for a period of about 15 (3 sets of 5 minutes) minutes in one sitting.
Study NCT05685121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Neuro
Description: The device is a wearable nerve stimulator.
Study NCT04748653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component reintegration intervention
Description: The intervention incorporates health education, psychosocial counseling, physiotherapy and economic investment.
Study NCT05379036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prescribing anapproved drug, examination
Description: * Blood test to assess serum zonulin levels;~* Esophagogastroduodenoscopyand colonoscopy with biopsy from the small and large intestine followed by histological examination;~* Stool sample collection to assess short-chain fatty acid levels and the composition of the gut microbiota.~Then the patients were prescribed therapy with the approved drug trimebutin (trimedat) with placebo or trimebutine with rebamipide or rebamipide with placebo for 2 months.
Study NCT05228067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal transcranial direct current stimulation
Description: anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
Study NCT05228067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cathodal transcranial direct current stimulation
Description: anodal tDCS of the hypothalamus resting-state functional connectivity network using 12 Electrodes of the Starstim device by Neuroelectrics. The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes.
Study NCT05228067 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Double blind sham stimulation of the hypothalamus resting-state functional connectivity network (ramp-up ramp-down stimulation will be applied for 30 seconds)
Study NCT05650502 — intervention group
Intervention type: DRUG
Intervention: saisonal malaria chimoprevention
Description: Investigate the impact of saisonal malaria chimoprevention on children anti PfEMP1 construction and maintenance and their succeptibility to malaria infection
Study NCT05115643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immobilization
Description: Immobilization of left arm using a brace and sling.
Study NCT06429644 — intervention group
Intervention type: PROCEDURE
Intervention: Breast-conserving surgery
Description: Breast-conserving surgery, also known as breast-conserving therapy or lumpectomy, is a surgical procedure used to treat breast cancer while preserving as much of the breast tissue as possible. During this procedure, the surgeon removes the cancerous tumor along with a surrounding margin of normal tissue. The goal is to remove the cancerous cells while maintaining the appearance and function of the breast as much as possible.
Study NCT05324917 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Chemotherapy for children with lymphoma: rituximab (375mg/m2 BSA) was added intravenously from COPADM1 regimen. once every 3 weeks to 4 weeks, combined with corresponding chemotherapy, a total of 4 times.
Study NCT05324917 — intervention group
Intervention type: DRUG
Intervention: Rituximab (once a week)
Description: Rituximab (375mg/m2 BSA) was administered intravenously for lymphoproliferative diseases and EB virus-associated B lymphoproliferative diseases after hematopoietic stem cell transplantation. Once a week, a total of 4 times.~ITP and AIHA patients received rituximab (100mg/m2 BSA) intravenously once a week, a total of 4 times.
Study NCT05630196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210
Description: Administered orally
Study NCT05630196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06174285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention with Psychedelic Virtual Reality
Description: A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
Study NCT06174285 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Therapeutic Intervention with Non-Psychedelic Virtual Reality
Description: A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
Study NCT05330689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection dose (<5 billion platelets)
Description: PRP injection with a dose of platelets that is less than 5 billion platelets
Study NCT05330689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection dose (between 5 and <10 billion platelets)
Description: PRP injection with a dose of platelets that is between 5 and \<10 billion platelets
Study NCT05330689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection dose (between 10 and <20 billion platelets)
Description: PRP injection with a dose of platelets that is between 10 and \<20 billion platelets
Study NCT05330689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection dose (20 billion or greater platelets)
Description: PRP injection with a dose of platelets that is 20 billion platelets or greater
Study NCT05330689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection control
Description: Saline control
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mandate public
Description: mandate by airlines, bars, restaurants
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: employer mandate
Description: your employer requires vaccination
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive reward
Description: $1,000 tax credit
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: penalty
Description: $1000 tax penalty
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive lottery small
Description: 100,000 smaller monetary amount
Study NCT04747327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive lottery medium
Description: 200,000 mid monetary amount